Annexon, Inc. (NASDAQ:ANNX) Receives Average Recommendation of “Buy” from Analysts

Shares of Annexon, Inc. (NASDAQ:ANNXGet Free Report) have earned an average recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $13.57.

A number of equities research analysts recently weighed in on ANNX shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Annexon in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Wednesday. Wells Fargo & Company raised their target price on shares of Annexon from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Wednesday. JPMorgan Chase & Co. upgraded shares of Annexon from a “neutral” rating to an “overweight” rating and set a $11.00 price target for the company in a research report on Friday, March 1st. Finally, Bank of America raised shares of Annexon from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $4.00 to $6.00 in a research report on Thursday, December 21st.

Check Out Our Latest Research Report on Annexon

Insider Buying and Selling at Annexon

In other news, CEO Douglas Love sold 5,782 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $5.54, for a total value of $32,032.28. Following the completion of the sale, the chief executive officer now owns 196,121 shares in the company, valued at approximately $1,086,510.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 8,940 shares of company stock valued at $49,514. 19.11% of the stock is owned by company insiders.

Institutional Trading of Annexon

A number of institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its position in Annexon by 31.3% in the first quarter. Tower Research Capital LLC TRC now owns 7,992 shares of the company’s stock worth $31,000 after acquiring an additional 1,903 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Annexon by 29.7% in the 4th quarter. Bank of America Corp DE now owns 8,938 shares of the company’s stock valued at $46,000 after purchasing an additional 2,049 shares in the last quarter. Quantbot Technologies LP increased its holdings in shares of Annexon by 630.8% in the 1st quarter. Quantbot Technologies LP now owns 9,500 shares of the company’s stock valued at $25,000 after purchasing an additional 8,200 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Annexon in the fourth quarter valued at about $46,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Annexon during the fourth quarter worth about $57,000.

Annexon Trading Up 13.5 %

Shares of Annexon stock opened at $7.81 on Thursday. The company has a fifty day simple moving average of $5.29 and a 200-day simple moving average of $3.65. The stock has a market cap of $415.80 million, a price-to-earnings ratio of -4.11 and a beta of 1.10. Annexon has a 12-month low of $1.57 and a 12-month high of $8.40.

Annexon Company Profile

(Get Free Report

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.

See Also

Analyst Recommendations for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.